49802-96-2 Usage
Uses
Used in Pharmaceutical Industry:
Propanoic acid, 2-methyl-2-(3-pyridinyloxy)is used as a key intermediate in the synthesis of various pharmaceuticals due to its unique chemical structure and functional groups. Its presence in the molecular framework can contribute to the development of new drugs with improved therapeutic properties.
Used in Agrochemical Industry:
In the agrochemical sector, Propanoic acid, 2-methyl-2-(3-pyridinyloxy)- is utilized as a building block for the development of new agrochemicals, potentially enhancing crop protection and yield.
Used in Organic Synthesis:
Propanoic acid, 2-methyl-2-(3-pyridinyloxy)is used as an intermediate in organic synthesis, allowing for the creation of a wide range of organic compounds for various applications, including specialty chemicals and materials.
Used in Fragrance and Flavor Production:
Propanoic acid, 2-methyl-2-(3-pyridinyloxy)is also used in the production of fragrances and flavors, where its unique chemical structure can contribute to the creation of novel scents and tastes for the consumer market.
Used in Neurodegenerative Disease Research:
Propanoic acid, 2-methyl-2-(3-pyridinyloxy)is being studied for its potential use in the treatment of neurodegenerative diseases, given its anti-inflammatory and analgesic properties, which may offer therapeutic benefits in managing such conditions.
Check Digit Verification of cas no
The CAS Registry Mumber 49802-96-2 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 4,9,8,0 and 2 respectively; the second part has 2 digits, 9 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 49802-96:
(7*4)+(6*9)+(5*8)+(4*0)+(3*2)+(2*9)+(1*6)=152
152 % 10 = 2
So 49802-96-2 is a valid CAS Registry Number.
49802-96-2Relevant academic research and scientific papers
PRO-DRUGS OF TERTIARY ALCOHOLS
-
Page/Page column 41, (2008/06/13)
The compounds of the present invention are prodrugs of modulators of the Cannabinoid-1 (CB 1 ) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the Cannabinoid- 1 (CB 1) receptor. In particular, compounds of the
Discovery of N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1- methylpropyl]-2-methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist for the treatment of obesity
Lin, Linus S.,Lanza Jr., Thomas J.,Jewell, James P.,Liu, Fing,Shah, Shrenik K.,Qi, Hongbo,Tong, Xinchun,Wang, Junying,Xu, Suoyu S.,Fong, Tung M.,Shen, Chun-Pyn,Lao, Julie,Xiao, Jing Chen,Shearman, Lauren P.,Stribling, D. Sloan,Rosko, Kimberly,Strack, Alison,Marsh, Donald J.,Feng, Yue,Kumar, Sanjeev,Samuel, Koppara,Yin, Wenji,Van Der Ploeg, Lex H. T.,Goulet, Mark T.,Hagmann, William K.
, p. 7584 - 7587 (2007/10/03)
The discovery of novel acyclic amide cannabinoid-1 receptor inverse agonists is described. They are potent, selective, orally bioavailable, and active in rodent models of food intake and body weight reduction. A major focus of the optimization process was to increase in vivo efficacy and to reduce the potential for formation of reactive metabolites. These efforts led to the identification of compound 48 for development as a clinical candidate for the treatment of obesity.
